Additional GVHD outcomes
| . | Itacitinib (n = 70) . | Systemic corticosteroids (n = 140) . | P value . |
|---|---|---|---|
| Maximum grade III/IV GVHD (n, %) | 6 (9%) | 15 (11%) | .81 |
| GVHD resistant to primary treatment through day 28 (n, %) | 8 (11%) | 20 (14%) | .67 |
| Flares (n, %)∗ | 7 (11%) | 14 (12%) | .88 |
| Cumulative prednisone dose (mg/kg) through day 28 (mean ± SEM) | 1.9 ± 0.6 | 22.0 ± 1.0 | <.001 |
| Cumulative prednisone dose (mg/kg) through day 56 (mean ± SEM) | 3.7 ± 1.2 | 30.0 ± 1.5 | <.001 |
| . | Itacitinib (n = 70) . | Systemic corticosteroids (n = 140) . | P value . |
|---|---|---|---|
| Maximum grade III/IV GVHD (n, %) | 6 (9%) | 15 (11%) | .81 |
| GVHD resistant to primary treatment through day 28 (n, %) | 8 (11%) | 20 (14%) | .67 |
| Flares (n, %)∗ | 7 (11%) | 14 (12%) | .88 |
| Cumulative prednisone dose (mg/kg) through day 28 (mean ± SEM) | 1.9 ± 0.6 | 22.0 ± 1.0 | <.001 |
| Cumulative prednisone dose (mg/kg) through day 56 (mean ± SEM) | 3.7 ± 1.2 | 30.0 ± 1.5 | <.001 |
Outcomes were monitored for 90 days unless otherwise stated. Flares of GVHD and GVHD resistant to primary treatment are defined as in “Methods.”
Flares are calculated among the subset of patients with a CR/PR after 28 days of systemic therapy without additional therapy: itacitinib (n = 62); SCS (n = 120).